Kidney function may change how VC005 drug works
NCT ID NCT07551570
First seen Jun 26, 2026 · Last updated Aug 21, 2026 · Updated 5 times
Summary
This early-stage study looks at how a single dose of VC005 tablets is processed in people with kidney impairment compared to those with normal kidney function. Researchers will measure drug levels in the blood and check safety. The goal is to understand if kidney problems affect how the drug behaves, which can guide future dosing.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- VC005 tablets
- What this could lead to
- If successful, this could help determine safe dosing of VC005 for people with kidney impairment.
- What could go wrong
- This is a very early Phase 1 study with only 32 people, so results may not apply broadly. It focuses on drug levels, not treatment effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
32 people
The number who actually took part.
- Started
-
May 2026
- Finished
-
Aug 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Voluntarily sign the informed consent form prior to the trial, fully understand the trial content, procedures, and possible adverse reactions, and be able to complete the study in accordance with the protocol requirements; 2. Participants (including their partners) are willing to have no pregnancy plan from screening until 3 months after the last study drug administration and voluntarily take effective contraceptive measures; and have no plans to donate sperm or eggs; 3. Male and female participants aged 18 to 70 years (inclusive); 4. Male participants weighing no less than 50.0 kg, female participants weighing no less than 45.0 kg. Body mass index (BMI) between 18 and 32 kg/m² (inclusive). Exclusion Criteria: 1. History of allergies, including to drugs, food, dust mites, etc., known allergy to the study drug or any of its components; 2. History of drug abuse, drug addiction and/or alcohol abuse (consumption of 14 units of alcohol per week: 1 unit = 285 mL beer, or 25 mL spirits, or 100 mL wine); positive results in drug abuse screening and alcohol screening; 3. Blood donation or significant blood loss (\> 400 mL) within 3 months prior to screening; or plan to donate blood during the trial; 4. Average daily smoking of more than 5 cigarettes within 3 months prior to screening; or inability to stop using any tobacco products during the trial; 5. History of recurrent herpes zoster, disseminated herpes zoster, or disseminated herpes simplex; 6. Known active bacterial, viral, fungal, parasitic infection or other infection, or any infectious event requiring antibiotic treatment or hospitalization (within 4 weeks prior to screening), or any acute infection within 2 weeks of baseline; 7. History of dysphagia or, within 6 months prior to screening, any gastrointestinal conditions affecting drug absorption or excretion (e.g., reflux esophagitis, peptic ulcer, chronic diarrhea, chronic constipation), history of liver disease (regardless of cure), and history of surgery (e.g., gastrointestinal surgery and other major surgeries).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Renal impairment are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, 233000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two blood tests may separate real kidney harm from a false alarm
- Can a damaged kidney change how a Weight-Loss drug works?
- Can a damaged kidney change how antibiotics work?
- Can kidney health change how a new drug works?
- Kidney function may change how D-2570 works in the body
- Sleep drug YZJ-1139 put to the test in kidney patients